Please assess the completion status of the following clinical trial:

Trial Title: Vaginal Progesterone for the Prevention of Preterm Birth in Women With Arrested Preterm Labor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Singleton or twin gestation~* Estimated gestational age between 24 0/7 and 33 6/7 weeks' gestation~* Initially present with regular contractions and clinical diagnosis of preterm labor but remain undelivered with 1) no further cervical change 12 hours after discontinuation of acute tocolytic therapy; or 2) be considered eligible for discharge based on attending physician judgment prior to the 12 hour period of time~* The participant's cervix must be at least 1 cm at the time of enrollment~Exclusion Criteria:~* Non-English speaking~* Rupture of membranes~* Chorioamnionitis~* Non-reassuring fetal status~* Maternal indication for delivery~* Placental abruption~* Intrauterine fetal demise~* Prenatally diagnosed major fetal anomaly~* Cervical cerclage in place~* Previous administration of progesterone during the current pregnancy for a history of preterm birth or short cervix~* Participant is either unwilling or unable to attend follow-up study visits following hospital discharge

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Micronized progesterone suppository (Type: ACTIVE_COMPARATOR): Micronized progesterone suppository 200 mg vaginally daily until 36 6/7 weeks' gestation.
- Placebo suppository (Type: PLACEBO_COMPARATOR): One placebo suppository vaginally daily until 36 6/7 weeks' gestation.

Based on this trial design, predict the completion outcome and termination type (if applicable).